DEVELOP A TUMOR-SUPPRESSIVE, EXTRACELLULAR, PROTEIN (TSEP) TO TREAT GBM
Led by Yi-Hong Zhou, PhD at The Regents of the University of California
The deadly brain cancer glioblastoma multiforme (GBM), for which there is not yet any
effective treatment, is made up of populations of different kinds of cells with distinct proliferating and infiltrative features. We have discovered that a protein (EFEMP) found in the matrix around tumor cells has the ability to retard tumor growth under certain conditions. This protein interacts with a number of other signaling proteins that impact tumor growth. Examination of the structure of EFEMP has revealed that it has various domains, which we have shown to be more or less important with regard to its antitumor activity, through the construction and testing of variant EFEMP proteins, which we have designated as ETSPs (EFEMP1-dertived tumor suppressive proteins). Our strategy of developing a new GBM therapeutant from ETSP is based on evaluation the effect on fast
proliferative and invasive tumor subpopulations separately and together in an orthotopic tumor formatting environment, and validates the results in paired subpopulations in other GBM-derived cell lines and primary cultures. This will make pre-clinical findings of ETSP more reproducible when applied in human GBM treatment.
Click here to view all of the grants VABC has funded